{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T06:19:49Z","timestamp":1788329989226,"version":"build-2803163510"},"reference-count":29,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,7,24]],"date-time":"2024-07-24T00:00:00Z","timestamp":1721779200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100017183","name":"Janssen Scientific Affairs LLC","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017183","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Oncology Nursing"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.soncn.2024.151712","type":"journal-article","created":{"date-parts":[[2024,8,17]],"date-time":"2024-08-17T11:35:53Z","timestamp":1723894553000},"page":"151712","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Nursing Considerations for the Clinical Management of Adverse Events Associated with Talquetamab in Patients with Relapsed or Refractory Multiple Myeloma"],"prefix":"10.1016","volume":"40","author":[{"given":"Donna","family":"Catamero","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chloe","family":"Ray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiah","family":"Purcell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheryl","family":"Leahey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elaine","family":"Esler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Rogers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kayla","family":"Hefner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"O'Rourke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen","family":"Gray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaszianne","family":"Tolbert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Renaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saurabh","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Hannemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samantha","family":"Shenoy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.soncn.2024.151712_bib0001","unstructured":"National Cancer Institute. Cancer stat facts: myeloma. Accessed April 1, 2024. https:\/\/seer.cancer.gov\/statfacts\/html\/mulmy.html; 2024."},{"key":"10.1016\/j.soncn.2024.151712_bib0002","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2021.102284","article-title":"Roadmap to cure multiple myeloma","volume":"100","author":"Rodriguez-Otero","year":"2021","journal-title":"Cancer Treat Rev"},{"issue":"1","key":"10.1016\/j.soncn.2024.151712_bib0003","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.clml.2019.09.621","article-title":"Treatment options for triple-class refractory multiple myeloma","volume":"20","author":"Mikhael","year":"2020","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"27","key":"10.1016\/j.soncn.2024.151712_bib0004","doi-asserted-by":"crossref","first-page":"4416","DOI":"10.1200\/JCO.23.00512","article-title":"Chimeric antigen receptor T-cell and bispecific antibody therapy in multiple myeloma: moving into the future","volume":"41","author":"Holstein","year":"2023","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.soncn.2024.151712_bib0005","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1186\/s12935-023-03045-y","article-title":"Safety and efficacy of T-cell-redirecting bispecific antibodies for patients with multiple myeloma: a systematic review and meta-analysis","volume":"23","author":"Noori","year":"2023","journal-title":"Cancer Cell Int"},{"issue":"26","key":"10.1016\/j.soncn.2024.151712_bib0006","doi-asserted-by":"crossref","first-page":"3681","DOI":"10.1182\/blood.2021014611","article-title":"T-cell-redirecting bispecific antibodies in multiple myeloma: a revolution?","volume":"139","author":"Moreau","year":"2022","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.soncn.2024.151712_bib0007","doi-asserted-by":"crossref","first-page":"2196","DOI":"10.1182\/bloodadvances.2020003805","article-title":"Preclinical activity and determinants of response of the GPRC5DxCD3 bispecific antibody talquetamab in multiple myeloma","volume":"5","author":"Verkleij","year":"2021","journal-title":"Blood Adv"},{"issue":"1","key":"10.1016\/j.soncn.2024.151712_bib0008","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/s41408-023-00966-9","article-title":"GPRC5D as a novel target for the treatment of multiple myeloma: a narrative review","volume":"14","author":"Rodriguez-Otero","year":"2024","journal-title":"Blood Cancer J"},{"issue":"15","key":"10.1016\/j.soncn.2024.151712_bib0009","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1182\/blood.2019003342","article-title":"A T-cell-redirecting bispecific G-protein-coupled receptor class 5 member D x CD3 antibody to treat multiple myeloma","volume":"135","author":"Pillarisetti","year":"2020","journal-title":"Blood"},{"issue":"suppl 1","key":"10.1016\/j.soncn.2024.151712_bib0010","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1182\/blood-2022-159707","article-title":"Talquetamab, a G protein-coupled receptor family C group 5 member D x CD3 bispecific antibody, in patients with relapsed\/refractory multiple myeloma (RRMM): phase 1\/2 results from MonumenTAL-1","volume":"140","author":"Chari","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.soncn.2024.151712_bib0011","unstructured":"US Food and Drug Administration. TALVEY (talquetamab-tgvs) injection [highlights of prescribing information]. Accessed August 9, 2024. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/761342s000lbl.pdf; 2023"},{"key":"10.1016\/j.soncn.2024.151712_bib0012","unstructured":"European Medicines Agency. TALVEY [summary of product characteristics]. Accessed February 15, 2024.https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/talvey-epar-product-information_en.pdf; 2024."},{"key":"10.1016\/j.soncn.2024.151712_bib0013","doi-asserted-by":"crossref","DOI":"10.1016\/j.clml.2024.05.003","article-title":"Clinical management of patients with relapsed\/refractory multiple myeloma treated with talquetamab","author":"Chari","year":"2024","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"24","key":"10.1016\/j.soncn.2024.151712_bib0014","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1056\/NEJMoa2204591","article-title":"Talquetamab, a T-cell-redirecting GPRC5D bispecific antibody for multiple myeloma","volume":"387","author":"Chari","year":"2022","journal-title":"N Engl J Med"},{"issue":"13","key":"10.1016\/j.soncn.2024.151712_bib0015","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1056\/NEJMoa2209900","article-title":"GPRC5D-targeted CAR T cells for myeloma","volume":"387","author":"Mailankody","year":"2022","journal-title":"N Engl J Med"},{"issue":"S3","key":"10.1016\/j.soncn.2024.151712_bib0016","doi-asserted-by":"crossref","DOI":"10.1097\/01.HS9.0000967684.98632.87","article-title":"S193: Bms-986393 (Cc-95266), a G protein\u2013coupled receptor class C group 5 member D (GPRC5D)\u2013targeted car T-cell therapy for relapsed\/refractory multiple myeloma (RRMM): results from a phase 1 study","volume":"7","author":"Bal","year":"2023","journal-title":"HemaSphere"},{"issue":"2","key":"10.1016\/j.soncn.2024.151712_bib0017","doi-asserted-by":"crossref","first-page":"e107","DOI":"10.1016\/S2352-3026(22)00372-6","article-title":"GPRC5D CAR T cells (OriCAR-017) in patients with relapsed or refractory multiple myeloma (POLARIS): a first-in-human, single-centre, single-arm, phase 1 trial","volume":"10","author":"Zhang","year":"2023","journal-title":"Lancet Haematol"},{"issue":"suppl 1","key":"10.1016\/j.soncn.2024.151712_bib0018","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1182\/blood-2022-157988","article-title":"RG6234, a GPRC5DxCD3 T-cell engaging bispecific antibody, is highly active in patients (pts) with relapsed\/refractory multiple myeloma (RRMM): updated intravenous (IV) and first subcutaneous (SC) results from a phase I dose-escalation study","volume":"140","author":"Carlo-Stella","year":"2022","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.soncn.2024.151712_bib0019","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1046\/j.0022-202X.2004.12628.x","article-title":"The RAIG family member, GPRC5D, is associated with hard-keratinized structures","volume":"122","author":"Inoue","year":"2004","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.soncn.2024.151712_bib0020","doi-asserted-by":"crossref","first-page":"S91","DOI":"10.1016\/S2152-2650(21)02229-1","article-title":"Normal human tissue expression of G protein-coupled receptor class C group 5 member D (GPRC5D), a promising novel target for multiple myeloma, is restricted to plasma cells and hard keratinized tissue [abstract]","volume":"21","author":"Goldsmith","year":"2021","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"2","key":"10.1016\/j.soncn.2024.151712_bib0021","doi-asserted-by":"crossref","first-page":"e143","DOI":"10.1016\/S2352-3026(21)00283-0","article-title":"Consensus guidelines and recommendations for infection prevention in multiple myeloma: a report from the International Myeloma Working Group","volume":"9","author":"Raje","year":"2022","journal-title":"Lancet Haematol"},{"issue":"1","key":"10.1016\/j.soncn.2024.151712_bib0022","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/s41408-023-00879-7","article-title":"Monitoring, prophylaxis, and treatment of infections in patients with MM receiving bispecific antibody therapy: consensus recommendations from an expert panel","volume":"13","author":"Raje","year":"2023","journal-title":"Blood Cancer J"},{"issue":"1","key":"10.1016\/j.soncn.2024.151712_bib0023","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s40425-018-0343-9","article-title":"Cytokine release syndrome","volume":"6","author":"Shimabukuro-Vornhagen","year":"2018","journal-title":"J Immunother Cancer"},{"issue":"6","key":"10.1016\/j.soncn.2024.151712_bib0024","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.jtct.2022.03.006","article-title":"Clinical presentation, risk factors, and outcomes of immune effector cell-associated neurotoxicity syndrome following chimeric antigen receptor T cell therapy: a systematic review","volume":"28","author":"Grant","year":"2022","journal-title":"Transplant Cell Ther"},{"issue":"4","key":"10.1016\/j.soncn.2024.151712_bib0025","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"2","key":"10.1016\/j.soncn.2024.151712_bib0026","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1182\/blood-2014-05-552729","article-title":"Current concepts in the diagnosis and management of cytokine release syndrome","volume":"124","author":"Lee","year":"2014","journal-title":"Blood"},{"issue":"508","key":"10.1016\/j.soncn.2024.151712_bib0027","doi-asserted-by":"crossref","first-page":"eaax8861","DOI":"10.1126\/scitranslmed.aax8861","article-title":"CD3 bispecific antibody-induced cytokine release is dispensable for cytotoxic T cell activity","volume":"11","author":"Li","year":"2019","journal-title":"Sci Transl Med"},{"issue":"1","key":"10.1016\/j.soncn.2024.151712_bib0028","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.annonc.2020.10.478","article-title":"Side-effect management of chimeric antigen receptor (CAR) T-cell therapy","volume":"32","author":"Schubert","year":"2021","journal-title":"Ann Oncol"},{"issue":"suppl 1","key":"10.1016\/j.soncn.2024.151712_bib0029","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1182\/blood-2023-181228","article-title":"Efficacy and safety of less frequent\/lower intensity dosing of talquetamab in patients with relapsed\/refractory multiple myeloma: results from the phase 1\/2 MonumenTAL-1 study","volume":"142","author":"Chari","year":"2023","journal-title":"Blood"}],"container-title":["Seminars in Oncology Nursing"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0749208124001840?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0749208124001840?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,14]],"date-time":"2024-09-14T11:01:51Z","timestamp":1726311711000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0749208124001840"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":29,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["S0749208124001840"],"URL":"https:\/\/doi.org\/10.1016\/j.soncn.2024.151712","relation":{},"ISSN":["0749-2081"],"issn-type":[{"value":"0749-2081","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Nursing Considerations for the Clinical Management of Adverse Events Associated with Talquetamab in Patients with Relapsed or Refractory Multiple Myeloma","name":"articletitle","label":"Article Title"},{"value":"Seminars in Oncology Nursing","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.soncn.2024.151712","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"151712"}}